Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
Tibes, Raoul
Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy? [electronic resource] - Leukemia & lymphoma Jul 2011 - 1178-87 p. digital
Publication Type: Journal Article; Review
1029-2403
10.3109/10428194.2011.566952 doi
Antineoplastic Agents--therapeutic use
Humans
Janus Kinase 2--antagonists & inhibitors
Leukemia--drug therapy
Mutation--genetics
Myeloproliferative Disorders--drug therapy
Neoplasm Staging
Primary Myelofibrosis--drug therapy
Protein Kinase Inhibitors--therapeutic use
Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy? [electronic resource] - Leukemia & lymphoma Jul 2011 - 1178-87 p. digital
Publication Type: Journal Article; Review
1029-2403
10.3109/10428194.2011.566952 doi
Antineoplastic Agents--therapeutic use
Humans
Janus Kinase 2--antagonists & inhibitors
Leukemia--drug therapy
Mutation--genetics
Myeloproliferative Disorders--drug therapy
Neoplasm Staging
Primary Myelofibrosis--drug therapy
Protein Kinase Inhibitors--therapeutic use